http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1506816-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c902faf6ae746c51fc8010672fc22894 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-4006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-5407 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-40 |
| filingDate | 1976-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1978-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1506816-A |
| titleOfInvention | Prostaglandins |
| abstract | 1506816 Prostaglandins UPJOHN CO 2 March 1976 [31 March 1975] 08324/76 Heading C2C [Also in Division C3] The invention comprises 16 - phenoxy- 17,18,19,20 - tetranorprostaglandins of the Formula I and mixtures comprising such compounds and enantiomers thereof, wherein R 1 is H, C 1-12 alkyl, C 3-10 cycloalkyl, C 7-12 aralkyl or phenyl optionally substituted 1 to 3 times by chlorine atoms or C 1-4 alkyl radicals; T is Cl, F, CF 3 , C 1-3 alkyl or C 1-3 alkoxy; s is 0 to 3 with the provisos that not more than two T's may be other than alkyl and the T's may be the same or different ; either X is trans CH = CH and Y is cis- CH = CH- or -CH 2 CH 2 -, or X and Y are both -CH 2 CH 2 -; g is 3, 4 or 5; R 4 and R 5 are H, methyl or ethyl, M 3 is wherein R 7 and R 8 each are H, methyl or ethyl with the proviso that they are not both H; and D is with the overall proviso that when the compounds are PGE and PGFα analogues, g is 4 or 5 and/or R 7 is methyl or ethyl; and pharmaceutically acceptable salts thereof when R 1 is H. The compounds are prepared by standard methods. 5α - Hydroxy - 4# - (3 - hydroxy - 3 - methyl - 4- phenoxy - trans - 1 - butenyl) - 3,3a#,4,6,6,6a#- hexahydro - 2H - cyclopenta[b]furan - 2 - ol is prepared by reducing the corresponding cyclopenta[b]furan-2-one. Prostaglandins of the formula wherein R 10 is 2-tetrahydropyranyl; M 1 is wherein R 11 is 2-tetrahydropyranyl, methyl or ethyl and Q is are obtained by reacting phosphonium salts of the formula with the appropriate cyclopenta[b]furan-2-ols of the formula The following intermediates are alsoprepared: cyclopenta[b]furans of the formulae wherein Z 1 is CR 4 R 5 -O-R 10 , in which R 10 is phenyl optionally substituted by Cl, F or CF 3 ; M 6 is = O, wherein R 11 is H or CH 3 , or and M 7 is where THP is 2-tetrahydropyranyl, 5α - hydroxy - 4# - (3 - hydroxy - 3 - methyl - 4- phenoxy - trans - 1 - butenyl) - 3,3a#,4,5,6,6a#- hexahydro - 2H - cyclopenta[b]furan - 2 - one and its bis - (2 - tetrahydropyranyl)ether; and 5α - hydroxy - 4# - (3 - methoxy - 4 - phenoxytrans 1 - butenyl) - 3,3a#,4,5,6,6a# - hexahydro - 2H - cyclopenta[b]furan - 2 - one and its 2-tetrahydropyranyl ether. Pharmaceutical compositions, suitable for oral, parenteral, rectal, vaginal and topical administration, contain the above prostaglandins or salts thereof together with pharmaceutically acceptable carriers. The compounds possess similar pharmacological properties to those of the naturally occurring prostaglandins. |
| priorityDate | 1975-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.